Department of Neurology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
Neurology Ward 2, Zhengzhou Yihe Hospital Affiliated to Henan University, Zhengzhou, Henan, China.
Pak J Pharm Sci. 2021 Sep;34(5(Special)):2053-2057.
To investigate the efficacy and safety of olanzapine, aripiprazole, and risperidone in the treatment of mental and behavioral symptoms of Alzheimer's Disease. A retrospective analysis was performed on the clinical data of 126 patients with Alzheimer's Disease from February 2018 to February 2020. The patients were divided into group A (aripiprazole, n=44), group B (olanzapine, n=42) and group C (risperidone, n=40) based on the treatment method. Remarkably differences at different time points among the three groups were observed (P<0.05). Significant differences in the Positive and Negative Syndrome Scale scores of different time points and cross-group comparison among the three groups were detected (P<0.05). The time-point comparison of BEHAVE-AD scores among the three groups indicated a remarkable difference (P<0.05). After 4 weeks of treatment, the Positive and Negative Syndrome Scale and BEHAVE-AD scores of group A were lower than those of groups B and C (P<0.05). The total incidence of adverse reactions in group A was remarkably lower than in groups B and C (P<0.05). Olanzapine, aripiprazole and risperidone are effective in treating Alzheimer's disease and aripiprazole, with a better safety profile and fewer adverse reactions, is more suitable for elderly patients.
探讨奥氮平、阿立哌唑和利培酮治疗阿尔茨海默病精神行为症状的疗效和安全性。对 2018 年 2 月至 2020 年 2 月收治的 126 例阿尔茨海默病患者的临床资料进行回顾性分析，根据治疗方法将患者分为 A 组（阿立哌唑，n=44）、B 组（奥氮平，n=42）和 C 组（利培酮，n=40）。三组在不同时间点的差异有统计学意义（P<0.05）。三组在不同时间点的阳性和阴性综合征量表评分及跨组比较差异有统计学意义（P<0.05）。三组的行为评定量表评分的时间点比较差异有统计学意义（P<0.05）。治疗 4 周后，A 组的阳性和阴性综合征量表及行为评定量表评分均低于 B 组和 C 组（P<0.05）。A 组的不良反应总发生率显著低于 B 组和 C 组（P<0.05）。奥氮平、阿立哌唑和利培酮治疗阿尔茨海默病均有效，其中阿立哌唑安全性更好，不良反应更少，更适合老年患者。
